| answer text |
<p>The interim clinical guidance, commissioned by NHS England and issued by the Royal
College of Physicians, British Paediatric Neurology Association and Association of
British Neurologists is based on the best available clinical evidence for safety,
efficacy and cost effectiveness and reflects clinical guidance that has been published
in other jurisdictions.</p><p> </p><p>The National Institute for Health and Care Excellence,
has been commissioned to develop guidelines for the National Health Service on the
prescribing of cannabis-based medicinal products by October 2019. This will update
and replace the interim guidance.</p>
|
 |
